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Abstract
Aims/hypothesis Innate immune effectors interact with the environment to contribute to the pathogenesis of the autoimmune disease,
type 1 diabetes. Although recent studies have suggested that innate immune Toll-like receptors (TLRs) are involved in tissue devel-
opment, little is known about the role of TLRs in tissue development, compared with autoimmunity. We aimed to fill the knowledge
gap by investigating the role of TLR9 in the development and function of islet beta cells in type 1 diabetes, using NOD mice.
Methods We generated Tlr9−/−NODmice and examined them for type 1 diabetes development and beta cell function, including
insulin secretion and glucose tolerance.We assessed islet and beta cell number and characterised CD140a expression on beta cells
by flow cytometry. We also tested beta cell function in Tlr9−/− C57BL/6 mice. Finally, we used TLR9 antagonists to block TLR9
signalling in wild-type NOD mice to verify the role of TLR9 in beta cell development and function.
Results TLR9 deficiency promoted pancreatic islet development and beta cell differentiation, leading to enhanced glucose
tolerance, improved insulin sensitivity and enhanced first-phase insulin secretory response. This was, in part, mediated by
upregulation of CD140a (also known as platelet-derived growth factor receptor-α [PDGFRα]). In the absence of TLR9, induced
by either genetic targeting or treatment with TLR9 antagonists, which had similar effects on ontogenesis and function of beta
cells, NOD mice were protected from diabetes.
Conclusions/interpretation Our study links TLR9 and the CD140a pathway in regulating islet beta cell development and
function and indicates a potential therapeutic target for diabetes prevention and/or treatment.
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Abbreviations
AM Acetoxymethyl
IPGTT Intra-peritoneal glucose tolerance test
ITT Insulin tolerance test
NGN3 Neurogenin 3
ODN Oligodeoxynucleotides
PDGF Platelet-derived growth factor
PDGFRα Platelet-derived growth factor receptor-α
PDX-1 Pancreatic and duodenal homeobox-1
qPCR Quantitative PCR
STZ Streptozotocin
TLR Toll-like receptor
WT Wild-type
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The innate immune system generates early inflammatory re-
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of innate immune receptors, including the Toll-like receptors
(TLRs), are important for immediate immune responses to
infection, leading to later, more specific, adaptive immunity.
On binding the appropriate ligand, the TLRs activate signal-
ling pathways that lead to production of proinflammatory cy-
tokines and upregulation of costimulatory molecules. TLRs
were initially thought to be expressed mainly on immune
cells, in particular antigen-presenting cells, but it is increas-
ingly recognised that they are also expressed on many other
cell types and have functions that range beyond activation of
the immune system. We, and others, have shown that pancre-
atic beta cells express many TLRs in both mice and humans
[1, 2]. Activation of TLR3, a receptor for double-stranded
RNA, has been shown to induce beta cell apoptosis [1, 3, 4].
TLR4, the receptor for endotoxin, is involved in regulation of
metabolism in a variety of tissues including beta cells [5–7].
TLR9 can also be detected easily in both mouse and human
islets [1, 2].
Type 1 diabetes is a slowly progressing autoimmune dis-
ease. We, and others, have independently shown that TLR9-
deficient (Tlr9−/−) NOD mice are protected from type 1 dia-
betes development [8–10]. This protection is mediated partly
by impaired IFNα production from Tlr9−/− mouse dendritic
cells [9] and by enhanced expression and regulatory function
of CD73+ Tcells [10]. However, increasing evidence suggests
that TLRs recognise not only exogenous ligands from mi-
crobes but also endogenous ligands from both normal and
damaged cells. Recent studies suggest that DNA released
from both physiological and pathological dying cells can be
a key stimulus to innate immune activation of TLR9 [11–14].
There is also evidence that TLRs regulate neurogenesis during
development [15]. Considering that islet beta cells undergo
significant growth and remodelling, early in life [16–19], it
is likely that TLR9 plays an important role in the development
of type 1 diabetes, beyond any direct immune function.
However, to date, there have been no reports about the role
of TLR9 in islet beta cell development. Therefore, we aimed
to assess the role of TLR9 in the development and function of
islet beta cells in both NOD and C57BL/6 mice.
Methods
Mice All the mice used in the study were housed in specific
pathogen-free conditions with a 12 h dark–light cycle and
were housed in individually ventilated filter cages with
autoclaved food and bedding at the Yale University animal
facility. The Tlr9− /− NOD mice were generated by
backcrossing Tlr9−/− C57BL/6 mice [20] with our NODmice,
for over 11 generations. The purity of the NOD genetic back-
ground was confirmed by mouse genome SNP scan with
Illumina Infinium panel (DartMouse, Lebanon, NH, USA).
Tlr9−/− NOD.Scid mice were generated by breeding Tlr9−/−
NOD mice with NOD.Scid mice, which were originally pur-
chased from the Jackson Laboratory (Bar Harbor, ME, USA)
and maintained at Yale University for ~25 years. Wild-type
(WT) C57BL/6 (Tlr9+/+ C57BL/6) mice were also purchased
from the Jackson Laboratory and maintained at Yale
University for ~10 years. The use of the animals in this study
was approved by the IACUC of Yale University. All mice
used in different experiments were randomly selected from
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different breeding cages and different litters. Experimenters
were not blinded in this study.
Natural history of diabetes development Tlr9−/− NOD mice
and Tlr9+/+ NOD littermates were screened for glycosuria
weekly for spontaneous diabetes development, up to 32weeks
of age. Diabetes was confirmed by blood glucose of
≥13.9 mmol/l with a FreeStyle glucose meter (Abbott,
Chicago, IL, USA).
Streptozotocin-induced diabetes development Female Tlr9−/−
NOD mice and Tlr9+/+ NOD littermates (5–6 weeks old) were
treated with either high-dose streptozotocin (STZ) (100 mg/kg,
administered by two consecutive i.p. injections, 24 h apart) or
low-dose STZ (40 mg/kg, administered by i.p. injection, once
daily, for 5 days). Mice were screened for glycosuria daily for
diabetes development and confirmed as above.
Intra-peritoneal glucose tolerance test Intra-peritoneal glu-
cose tolerance tests (IPGTTs) were performed in 5–6-week-
old Tlr9−/− NOD, Tlr9+/+ NOD, Tlr9−/− C57BL/6, Tlr9+/+
C57BL/6, Tlr9−/− NOD.Scid and Tlr9+/+ NOD.Scid mice.
The mice were fasted overnight with free access to water
and the blood glucose was measured before (time zero) and
after i.p. injection of glucose (1 g/kg) at different time points
from blood samples. Blood glucose was measured by a
FreeStyle glucose meter (Abbott). Data are shown from one
out of three experiments, each confirming the significant
difference.
Insulin tolerance test Insulin tolerance tests (ITTs) were per-
formed in 5–6-week-old male Tlr9−/− C57BL/6 mice and
Tlr9+/+ C57BL/6 mice. The mice were fasted for 6 h with free
access to water and the blood glucose was measured before
and after i.p. injection of insulin (Humulin-R, 0.75 U/kg; Eli
Lilly, Indianapolis, IN, USA) at different time points, as de-
scribed for IPGTT.
Islet and beta cell isolation Pancreatic islets were isolated as
previously described [21]. Mice were euthanised by cervical
dislocation. The pancreas was inflated with 3 ml cold collage-
nase (Sigma; St Louis, MO, USA) solution (0.3 mg/ml)
through the bile duct with a 20G needle starting at the gall
bladder. The pancreas was then removed into a siliconised
glass tube containing 2 ml of 1 mg/ml collagenase solution
and digested at 37°C in a water bath for 12–15 min. After
three washes of the digested pancreas, islets were hand-
picked and counted under a dissecting microscope for further
experiments. For single-cell isolation, the islets were treated
with Cell Dissociation Solution (Sigma) and the single-cell
suspension was harvested. Beta cells from the dissociated is-
lets were stained with fluorochrome-conjugated monoclonal
antibodies to CD45 (BioLegend; San Diego, CA, USA),
CD140a (BioLegend) and FluoZin-3-acetoxymethyl (AM)
(CD45−FluoZin-3-AM+; ThermoFisher, Waltham, ME,
USA) [22] before being analysed by flow cytometry (LSRII;
BD Bioscience, San Diego, CA, USA).
Quantitative PCR Pancreatic islets were isolated as described
above. RNA from islets of 3–4-week-old female Tlr9+/+NOD
mice and Tlr9−/− NOD mice was extracted with an RNAeasy
kit (Qiagen, Hilden, Germany) and quantified by NanoDrop
(ThermoFisher). Equal amounts of RNA were reverse tran-
scribed using SuperScript III First-strand synthesis kit with
random hexamers (Invitrogen, Carlsbad, CA, USA).
Quantitative PCR (qPCR) was performed using the Bio-Rad
iQ5 qPCR detection system (Hercules, CA, USA) with the spe-
cific primers for Pdx-1 (also known as Pdx1) (5′-CAGC
AGAACCGGAGGAGAAT-3′ and 5′-CGACGGTTTTGGAA
CCAGAT-3′) and Ngn3 (also known as Neurog3) (5′-CCCG
CAGCTCTCTGTTCTTT-3′ and 5′-GGGTCTCTTGGGAC
ACTTGG-3′) (Sigma). The relative expression of mRNA
levels was determined with the 2−ΔΔCt method by normal-
isation with the housekeeping gene Gapdh (5′-AGGT
CGGTGTGAACGGATTTG - 3 ′ a n d 5 ′ - T G TA
GACCATGTAGTTGAGGTCA-3′).
Cell staining for flow cytometry
For direct staining, single-cell suspensions (~5 × 104 to 2 ×
105 cells) of immune cells or islet cells were incubated with a
2.4G2 Fc-blocking antibody (10 mins, room temperature) pri-
or to staining with pre-titrated amounts of monoclonal anti-
bodies conjugated with different fluorochromes to combina-
tions of CD3 (17A2), CD4 (GK1.5), CD44 (IM7), CD45 (30-
F11) CD62L (MEL-14), CD140a (APA5) and a viability dye
(all from BioLegend) in staining buffer (PBS containing 1%
FCS) and kept on ice and in the dark for 30 min. The cells
were washed twice with 2 ml staining buffer and fixed with
200 μl fixation buffer (eBioScience; San Diego, CA, USA)
before analysis by flow cytometry. All antibodies were titrated
using mouse splenocytes at different dilutions with the final
dilution applied found to be most appropriate for the particular
batch of antibody used and our flow cytometer set up.
Intracellular staining For intracellular staining, the single-cell
suspension was treated with Perm/Fix buffer (eBioscience)
followed by pre-titrated monoclonal antibodies conjugated
with different fluorochromes to FoxP3 (FJK-16S,
eBioscience) or FluoZin-3-AM (ThermoFisher). After
30 min incubation on ice or at room temperature, the cells
were washed twice with 2 ml staining buffer and analysed
by flow cytometry. FoxP3 was titrated using mouse
splenocytes at different dilutions with the final dilution ap-
plied found to be appropriate for the batch used and our flow
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cytometer set up. For Fluozin-3-AM, mouse islets were used
to titrate the antibody, with 1:2000 dilution used found to be
appropriate for the particular batch of antibody used and our
flow cytometer set up. Dilutions were determined where they
gave the clearest separation from the negative background or
isotype control.
Insulin release assay An insulin release assay was performed
as previously described [23] with modification. Hand-picked
pancreatic islets from randomly selected Tlr9−/− and Tlr9+/+
NOD or C57BL/6 mice (5–6 weeks old) were equally distrib-
uted to 30 islets/tube after stabilising with low-glucose KRB
buffer. The islets were then stimulated with KRB containing
high glucose (25 mmol/l) and the supernatant fractions were
harvested every 5 min after glucose stimulation. Secreted in-
sulin in the supernatant fractions was measured using the in-
sulin RIA kit (EMD-Millipore, Burlington, ME, USA).
Evaluation of islet mass Ex vivo pancreases from randomly
selected 5–6-week-old female Tlr9−/− NOD and Tlr9+/+ NOD
mice were fixed in periodate–lysine–paraformaldehyde, su-
crose infused and then frozen in Tissue-Tek OCT (Bayer,
Elkhart, IN, USA). The pancreas was cut in its entirety into
hundreds of 10 μm thick sections and every tenth section was
stained with haematoxylin alone (to better visualise the islets)
and photographed under the microscope. Islet mass was mea-
sured using Image J software (NIH, Bethesda, MD, USA).
H&E staining of sections was conducted purely for improving
the contrast of the images for the photographs presented in
Fig. 4b.
In vitro TLR9 antagonist treatment Freshly isolated islets from
Tlr9+/+ NOD mice (5-week-old females) were cultured over-
night with the TLR9 antagonist CpG- oligodeoxynucleotides
(ODN) (2088; Invivogen, San Diego, CA, USA) or control
CpG-ODN (Invivogen), both at 10 μg/ml. After extensive
washing, a single-cell suspension was prepared as described
earlier and stained with fluorochrome-conjugated monoclonal
antibodies to CD45, CD140a and FluoZin-3-AM before anal-
ysis by flow cytometry. Another set of freshly isolated islets
from Tlr9+/+ NOD mice was used for insulin release assay,
after overnight culture in the presence of the TLR9 antagonist
CpG-ODN or control CpG-ODN.
In vivo treatment with TLR9 antagonist or chloroquine and
diabetes development Randomly chosen Tlr9+/+ female
NOD mice were treated with TLR9 antagonist CpG-ODN
(2088) or control ODN, 10 μg/mouse, administered as two
i.p. injections, 3 days apart, 1 week after mating. Another set
of randomly chosen Tlr9+/+ pregnant female NOD mice were
treated with chloroquine (20 μg/g body weight), administered
as two i.p. injections, 3 days apart. The female offspring from
the treated mothers were investigated for CD140a-expressing
islet beta cells, the number of islet beta cells and insulin-
secreting function at ~5 weeks old. A third group of randomly
chosen pregnant female Tlr9+/+ NOD mice were also treated
with antagonist CpG-ODN or control ODN and the natural
history of diabetes development was observed in the female
progeny of the treated pregnant mice.
Statistical analysis No data were excluded and all viable mice
within the different genotypes were included, with the excep-
tion of any obvious runts or under-developed mice. No out-
comes or conditions were measured or used that are not re-
ported in the results section. Statistical analyses were per-
formed using GraphPad Prism software (San Diego, CA,
USA). Diabetes incidence was compared using logrank test.
The in vivo and in vitro assays were analysed with Student’s
unpaired t test or ANOVA for statistical significance.
Results
TLR9 deficiency suppressed type 1 diabetes development and
enhanced islet beta cell function Although the environment
influences type 1 diabetes development [24], particularly in
NOD mice, which are very sensitive to environmental chang-
es [25], the protection from diabetes development seen in
Tlr9−/− NOD mice has been consistent in our mouse colony
over many years (Fig. 1a, b). This implies that environmental
variation, including housing status (data not shown), does not
play a major role in this protection. To test the hypothesis that,
beyond its function in innate immunity, TLR9 may impact on
pancreatic beta cells and investigate the role of TLR9 in islet
beta cell function, we performed glucose tolerance tests
(GTTs). Tlr9−/− NOD mice had significantly better glucose
tolerance, on glucose stimulation in vivo, than their Tlr9+/+
NOD (WT) littermates (Fig. 1c, d), at 5–6 weeks of age, when
there is little beta cell destruction in the Tlr9+/+ NODmice. To
confirm that the improved glucose tolerance in Tlr9−/− NOD
mice was not due to the reduced insulitis in these mice [10],
we generated Tlr9−/−NOD.Scid mice, which are completely
free of lymphocytic infiltration. We tested glucose tolerance
in Tlr9−/− NOD.Scid mice and Tlr9+/+ NOD.Scid mice, nei-
ther of which develop insulitis nor diabetes. The Tlr9−/−
NOD.Scid mice demonstrated significantly better glucose tol-
erance than their Tlr9+/+ NOD.Scid counterparts (Fig. 1e, f),
similar to immune-sufficient Tlr9−/− NOD mice.
To test whether the improved beta cell function in the ab-
sence of TLR9 was related to the NOD genetic background,
we studied Tlr9+/+ C57BL/6 mice and Tlr9−/− C57BL/6 mice.
Interestingly, we consistently found enhanced glucose toler-
ance in Tlr9−/− mice, regardless of their genetic background
(Fig. 2a, b). Next, we investigated in vitro insulin secretion of
islet beta cells, in response to glucose stimulation. Pancreatic
islets isolated from young Tlr9+/+ NOD mice and Tlr9−/−
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NOD mice were cultured in high glucose concentrations and
insulin release into the culture supernatant fractions was mea-
sured every 5 min. Consistent with the in vivo GTT results,
more insulin was secreted from the islets isolated from both
Tlr9−/− NOD and Tlr9−/− C57BL/6 mice vs Tlr9+/+ NOD and
C57BL/6 mice (Fig. 2c, d). To further assess the insulin sen-
sitivity, we also conducted an ITT and found improved glu-
cose control in Tlr9−/− C57BL/6 mice vs Tlr9+/+ C57BL/6
mice (Fig. 2e).
Increased islet and beta cell number in the absence of TLR9 in
NOD mice Based on our findings of enhanced beta cell func-
tion, we hypothesised that, in the absence of TLR9, beta cells
were either more resistant to cell death or had increased cell
growth. To investigate beta cell death, we treated Tlr9+/+
NOD and Tlr9−/− NOD mice with STZ, a chemical causing
beta cell death leading to clinical diabetes. However, there was
no particular resistance to beta cell death in Tlr9−/−NODmice,
as diabetes onset was similar to the onset in their Tlr9+/+NOD
counterparts after STZ treatment, both at high dose and mul-
tiple low doses (Fig. 3a, b). We also investigated islet apopto-
sis in response to STZ, directly ex vivo. Freshly isolated islet
cells from Tlr9+/+ NOD and Tlr9−/− NOD mice were cultured
with STZ (40 ng/ml) for 3 h followed by staining for apoptosis
using Annexin Vand 7-AAD. In line with the results from the
in vivo experiments, islet cells from Tlr9−/− NOD mice were
as susceptible to apoptosis as the islet cells from Tlr9+/+ NOD
mice (Fig. 3c).
Next, we investigated the alternative possibility of in-
creased cell growth by analysing the islet mass. OCT-
embedded frozen pancreatic tissue blocks from young
Tlr9+/+ NOD and Tlr9−/− NOD mice were completely sec-
tioned at 10 μm/section and stained with haematoxylin alone
to better visualise the islets. We examined every tenth section
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under light microscopy and measured the islet area. The data
were analysed with ImageJ software. Interestingly, we discov-
ered a significant increase in islet mass of the pancreases from
Tlr9−/− NOD mice compared with their Tlr9+/+ NOD coun-
terparts (Fig. 4a). The presence of more islets in Tlr9−/− vs
Tlr9+/+ NOD mouse pancreases (Fig. 4b) contributed to the
increased islet mass observed in Tlr9−/− NOD mice as exam-
ined by H&E staining. We also examined the number of beta
cells per pancreas by flow cytometry. Consistent with the islet
mass results, the number of beta cells per mouse was much
higher in Tlr9−/− NOD mice than in Tlr9+/+ NOD mice
(Fig. 4c). To confirm the association of TLR9 deficiency with
islet beta cell development, we examined the expression of
genes encoding pancreatic and duodenal homeobox-1 (PDX-
1) and neurogenin 3 (NGN3), two transcription factors known
to play an important role in islet beta cell development
[26–28]. We compared the expression levels of Pdx-1 and
Ngn3 mRNA in dispersed islet cells (5 × 105) of freshly
hand-picked islets from the pancreases of young WT and
Tlr9−/− NOD mice, by qPCR. As predicted, the expression
of Pdx-1 and Ngn3 was significantly higher in islet cells from
Tlr9−/−NODmice compared with Tlr9+/+ NODmice (Fig. 4d,
e). Taken together, our data suggested that TLR9 negatively
regulates islet beta cell development and, in the absence of
TLR9, islet mass is increased, which leads to enhanced insulin
secretion and islet beta cell function.
Increased islet beta cells expressing CD140a in the absence of
TLR9 in NOD mice We next investigated the molecular path-
way(s) by which TLR9 could influence pancreatic islet devel-
opment. We focused on CD140a (also known as platelet-
derived-growth-factor receptor-α [PDGFRα]), as it has been
reported to control proliferation of pancreatic beta cells [29].
We examined CD140a expression on dispersed beta cells from
Tlr9+/+ NOD and Tlr9−/−NOD mice, using anti-mouse-
CD140a and the beta cell marker FluoZin-AM [30], and
analysed the cells by flow cytometry. FluoZin-AM is a zinc-
selective fluoroionophore that can detect the high concentration
of zinc present in the insulin granules within beta cells [31]. We
found that more beta cells from Tlr9−/− NOD mice expressed
CD140a than their Tlr9+/+ NOD counterparts (Fig. 5a, b).
Based on these results, we hypothesised that inhibition of
TLR9 signalling in Tlr9+/+NOD mice may induce CD140a
expression on beta cells and enhance their function. To test
our hypothesis, we cultured the islets from Tlr9+/+ NOD mice
with the TLR9 antagonist CpG-ODN 2088 or control CpG-
ODN overnight and examined CD140a expression. It is inter-
esting that the TLR9 antagonist was indeed able to induce
CD140a expression on Tlr9+/+ islets (Fig. 5c, d). Next, we
tested the function of beta cells from TLR9 antagonist-treated
WT islets by measuring insulin secretion in response to glucose
stimulation. Pancreatic islets isolated from young Tlr9+/+NOD
mice were cultured with TLR9 antagonist ODN or control
ODNovernight. After extensivewashing, the islets were further
cultured in high glucose concentrations and insulin release into
the culture supernatant fractions was measured every 5 min.
Figure 5e shows that early-phase insulin secretion in response
to glucose stimulation was significantly enhanced in Tlr9+/+
NOD islets treated with TLR9 antagonist. To test whether inhi-
bition of CD140a could reverse the effect of TLR9 antagonist
on beta cells, we cultured islets from young Tlr9+/+ NOD and
Tlr9−/− NODmice with a CD140a inhibitor (PDGFR inhibitor,
Enzo Life Science, Oyster Bay, NY, USA), as we had done with
the TLR9 antagonist. However, due to the cell toxicity of the
inhibitor, most of the islet cells were not viable after overnight
culture (data not shown).
Treatment with TLR9 antagonist resulted in increased
CD140a-expressing islet beta cells and number of beta cells,
improved beta cell function and protected Tlr9+/+ NOD mice
from diabetes development A study by Chen and colleagues
suggested that the expression of CD140a on islet beta cells
was age-dependent [29]. We hypothesised that the enhanced
development of pancreatic islets and the increased number of
CD140a-expressing beta cells in Tlr9−/− NOD mice occur
early in life. To test this in vivo, we treated Tlr9+/+NODmice
with TLR9 antagonist CpG-ODN and its control CpG-ODN
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(100 mg/kg, two i.p. injections) in 5–6-week-old female Tlr9−/− NOD
mice (black circles; n = 5 mice) and Tlr9+/+ NOD littermates (white cir-
cles; n = 5 mice). (b) Incidence of diabetes development induced by low-
dose STZ (40 mg/kg, five i.p. injections) in 5–6-week-old female Tlr9−/−
NODmice (black circles; n = 7 mice) and Tlr9+/+ NOD littermates (white
circles; n = 7 mice). (c) Apoptosis of islet cells in response to STZ (40 ng/
ml) insult in vitro determined by Annexin V and 7-AAD staining (n = 4
mice per group). White circles, live cells (Annexin V−/7-AAD−); grey
triangles, early apoptotic cells (Annexin V+/7-AAD−); inverted white
triangles, late apoptotic cells (Annexin V−/7-AAD+); black circles, dead
cells (Annexin V+/7-AAD+). All experiments were performed once. Data
in (c) are expressed as means (SD). Data in (a, b) were analysed by
logrank test for survival and in (c) by two-tailed unpaired Student’s t test
(NS for all)
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prenatally (i.e. during fetal development). We injected female
Tlr9+/+ NOD mice, 1 week after mating, with CpG-ODN
2088 or control CpG-ODN (10 μg/mouse, i.p., twice a week
for 2 weeks) and examined the numbers of beta cells and
CD140a-expressing beta cells from the young female progeny
(5 weeks old). No adverse effects were observed in mice re-
ceiving this treatment. In line with our findings in Tlr9−/−
NOD mice, we demonstrated an increase in the number of
CD140a-expressing islet beta cells, as well as the number of
islets and beta cells per mouse, in the mice that received TLR9
antagonist ODN during embryonic development (Fig. 6a, b).
To test whether the function of beta cells was also improved,
we performed insulin release assays. Consistent with the re-
sults found in Tlr9−/− NOD mice, TLR9 antagonist treatment
in Tlr9+/+ NOD mice also enhanced beta cell function, as
demonstrated by the secretion of significantly more insulin
in response to glucose stimulation (Fig. 6c). Furthermore,
the offspring of the Tlr9+/+ NOD mice treated with TLR9
antagonist CpG-ODN had significantly delayed and overall
lower incidence of diabetes than the progeny of the mice treat-
ed with control CpG-ODN (Fig. 6d). We have previously
shown that TLR9 deficiency increases the expression levels
of CD73, which is also expressed on regulatory T cells, and
that TLR9-deficient mice are protected from diabetes [10].
Given the finding that islet beta cell number and function are
increased by TLR9 antagonist treatment, we examined
immune variables in the mice treated with TLR9 antagonist.
We found that the percentage of regulatory T cells was in-
creased in the islets of the mice whose mothers had received
TLR9 antagonist ODN during pregnancy, although the in-
crease was not statistically significant (Fig. 7a). Interestingly,
the naive andmemory CD4+ Tcells in the spleen of these mice
showed significant changes when compared with the progeny
of control ODN-treated mice (Fig. 7b, c). It is known that
chloroquine acts as a TLR9 inhibitor. Therefore, to test wheth-
er chloroquine could also promote islet and beta cell develop-
ment, we prenatally treated pregnant Tlr9+/+ NOD mice with
chloroquine (i.p. injection, 20 μg/g body weight, twice with a
3 day interval) and assessed the number of islets and beta cells
from the female progeny at ~5 weeks of age. It is intriguing
that chloroquine had very similar effects to the TLR9 antago-
nist ODN on the development of islet beta cells, including
increasing the proportion of CD140a-expressing islet beta
cells (Fig. 8a) and increasing the numbers of islets and beta
cells (Fig. 8b, c). Thus, our results suggest that blocking TLR9
signalling promotes islet beta cell development.
Discussion
In this study, we have identified a novel function of TLR9,
quite distinct from its role in innate immunity. We showed that
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Fig. 4 TLR9-deficiency promotes beta cell development. (a)
Photographs were taken of pancreatic sections after staining with
haematoxylin alone to visualise the islets better. Islet area was evaluated
by ImageJ software. More islets were present in the pancreases of Tlr9−/−
NOD mice (black diamonds) compared with Tlr9+/+ NOD mice (black
circles) (p < 0.001). (b) Representative pancreas sections after staining
with H&E are shown. Scale bar, 100 μm. (c) Beta cells from pancreatic
islets of 4-week-old female Tlr9+/+ NOD and Tlr9−/− NOD mice (n = 4
mice for both groups) were harvested after treatment with Cell
Dissociation Solution (Sigma). After staining with anti-CD45 and
FluoZin-AM, beta cells (CD45−FluoZin+ cells) were enumerated by flow
cytometry. Beta cell number was increased in the pancreas of Tlr9−/−
NOD mice when compared with Tlr9+/+ NOD mice. (d, e) Total cellular
RNAwas extracted from islets of ~4-week-old female Tlr9+/+ NOD and
Tlr9−/− NOD mice and qPCR was conducted with specific primers for
transcription factors for beta cell development, Pdx-1 (d) and Ngn3 (e).
The relative expression level of mRNAwas determined by normalisation
with the housekeeping gene, Gapdh. The expression of both Pdx-1 and
Ngn3 was increased in pancreatic islets of Tlr9−/− NOD mice when com-
pared with Tlr9+/+ NODmice (p = 0.01). The experiments shown in (c–e)
were performed twice, with results from one of the experiments being
shown. Data in (c–e) are expressed as means (SD). Data were analysed in
(a) by two-way ANOVA and in (c–e) by two-tailed unpaired Student’s
t test. *p < 0.05, ***p < 0.001
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TLR9-deficient mice have more pancreatic islets and, corre-
spondingly, more islet beta cells, with increased glucose-
stimulated insulin secretion in vitro and improved glucose
tolerance in vivo. This was not due to increased resistance to
beta cell death. Rather, we found increased expression of
genes encoding PDX-1 and NGN3, transcription factors asso-
ciated with beta cell development, suggesting that the increase
in beta cell mass was related to promotion of beta cell growth.
Although many growth factors regulate islet beta cell
development [28, 32], in linking TLR9 deficiency and islet
beta cell development, we found that the proportion of islet
beta cells expressing CD140a was increased in TLR9-
deficient mice. Confirming that this effect was associated with
TLR9 deficiency, we showed, using TLR9 antagonism, that
inhibition of the TLR9 signalling pathway in islets from
TLR9-sufficient mice led to an increased number of
CD140a-expressing beta cells and enhanced insulin secretion
in response to glucose stimulation. Our results thus demon-
strate a novel link between TLR9 and CD140a, a growth fac-
tor that has been reported to regulate islet beta cell prolifera-
tion [29].
Islet beta cells display distinct phases of significant growth
in the fetal and neonatal periods, whereas there is little in-
crease in islet beta cell numbers in adulthood in either mice
or humans [33, 34]. Proliferation and survival are among the
functions promoted by platelet-derived growth factor (PDGF)
signalling through the PDGF receptors, of which CD140a is
one of two main receptor isoforms for PDGF. This is a
20
WT
Ctrl ODN
11.5% 17.6%
12.8% 19.7%
15
10
5
0
C
D
1
4
0
a
+
 b
e
ta
 c
e
ll
s
/
m
o
u
s
e
 (
%
)
***
***
***
15
10
5
0
Ctrl
ODN
Antagonist
ODN
C
D
1
4
0
a
+
 b
e
ta
 c
e
ll
s
/
m
o
u
s
e
 (
%
)
10
0
20
30
40
50
0 10 20 30 40
Time (min)
Fluozin
Fluozin
CD140a
CD140a
Tlr9
+/+ 
NODTlr9
-/- 
NOD
In
s
u
li
n
 r
e
le
a
s
e
(
U
 i
s
le
t-
1
 m
in
-
1
)
Tlr9
-/-
a b
c
e
d
Fig. 5 CD140a is highly expressed in Tlr9−/− islets. (a, b) CD140a ex-
pression on islet beta cells from Tlr9+/+ NOD and Tlr9−/− NOD mice.
Pancreatic islets were isolated from ~4-week-old female Tlr9+/+ NOD
and Tlr9−/−NOD mice and beta cells were harvested after treatment with
Cell Dissociation Solution (Sigma). The cells were stained with mono-
clonal antibodies to CD45, CD140a and FluoZin-AM and analysed by
flow cytometry. CD45− cells (non-haematopoietic cells) were gated and
the expression of CD140a on FluoZin+ beta cells is shown (a).
Quantification of CD140a+ beta cells in Tlr9+/+ NOD and TLR9−/−
NOD mice (b) (p = 0.0002; n = 4 mice [pooled into two samples] per
group per experiment), with two experiments being performed). (c, d)
CD140a expression on islet beta cells from Tlr9+/+ NOD mice treated
with control (Ctrl) ODN or antagonist ODN. Isolated islets from Tlr9+/+
NOD mice were cultured with TLR9 antagonist ODN or control ODN
(both at 10 μg/ml) overnight. Islet beta cells were harvested after disso-
ciation and stained with monoclonal antibodies to CD45, CD140a and
FluoZin-AM. CD140a expression is shown on FluoZin+ beta cells after
gating on CD45− cells (c). Quantification of CD140a+ beta cells after
treatment with TLR9 antagonist ODN or control ODN (d) (p < 0.001;
n = 7 mice per group per experiment; data are from two experiments).
(e) Insulin release assay of islets treated with control ODN (white circles;
n = 7 mice) or antagonist ODN (black circles; n = 7 mice) (p < 0.001).
Two-tailed unpaired Student’s t test was used for (a–d) and two-way
ANOVAwas used for (e). Data in (b) and (d) are expressed as the actual
numbers, with the mean indicated as the line in the figures. Data in (e) are
expressed as means (SD). ***p < 0.001
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Fig. 6 Treatment of Tlr9+/+ NOD mice with TLR9 antagonist recapitu-
lated Tlr9−/− phenotypes in vivo. (a) Treatment with TLR9 antagonist
enhances CD140a expression on islet beta cells from Tlr9+/+ NOD mice.
CD140a expression on islet beta cells from the female progeny (5–
6 weeks old) of TLR9 antagonist ODN- or control (Ctrl) ODN-treated
pregnant NOD mice (p = 0.0095; n = 7 mice for both groups). (b) TLR9
antagonist treatment increases beta cell number. Number of beta cells/
mouse in the female progeny (5–6 weeks old) of TLR9 antagonist ODN-
or Ctrl ODN-treated pregnant NOD mice (p = 0.044; n = 6 mice for both
groups). (c) TLR9 antagonist treatment enhances beta cell function.
Insulin release from islets from the female progeny (5–6 weeks old) of
TLR9 antagonist ODN- (black circles) or Ctrl ODN-treated (white cir-
cles) pregnant NOD mice (p = 0.0007; n = 6 mice for both groups). (d)
TLR9 antagonist treatment prevents spontaneous type 1 diabetes devel-
opment. Pregnant NOD mice (n = 3) were treated with TLR9 antagonist
ODN and the incidence of diabetes was monitored in the female progeny
(p = 0.019) (black circles; n = 10 mice) or Ctrl ODN (white circles, n = 7
mice). Two independent experiments were performed in (a–c), n = 3–4
mice per group per experiment. Data were analysed in (a, b) by two-tailed
unpaired Student’s t test, in (c) by two-way ANOVA and in (d) by logrank
test for survival. Data are expressed in (a) and (b) as means (horizontal
line) and in (c) as means (SD). *p < 0.05, **p < 0.01, ***p < 0.001
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receptor tyrosine kinase and it is expressed in cells of mesen-
chymal origin, including the pancreas [35]. It has been sug-
gested that the human CD140a promoter has a binding site for
c-Rel [36], which is a subunit of the NFκB protein complex
and plays an important role in development, immunity and
diseases, including type 1 diabetes [37–39]. Expression of
CD140a is normally age-dependent in mouse pancreatic islet
beta cells, reaching a peak at around the age of 2 weeks and
declining once mice reach adulthood [29]. If this receptor is
lost prematurely, as shown by gene mutation experiments,
beta cell proliferation and expansion are impaired [29]. Our
current results suggest that TLR9 may be one of the factors
involved in the control of the age-dependent expression of
CD140a, and may negatively regulate the expression of
CD140a. Blocking TLR9 signalling, either by genetic
targeting or by inhibition via small molecules early in life,
results in an increase in CD140a expression and a correspond-
ing increase in islet beta cells later in life.
There is increasing evidence to suggest that TLRs not only
recognise exogenous ligands from microbes but also recog-
nise endogenous ligands from both normal and damaged cells.
As TLR9 recognises CpG motifs, present in bacterial DNA or
endogenous DNA, that are released from both physiological
and pathological dying cells [40], it could play a role in tissue
remodelling. Although the gut microbiota differs in composi-
tion when comparing Tlr9−/− NOD and Tlr9+/+ NOD mice,
protection from diabetes and enhanced beta cell development
and function were not associated with this difference (data not
shown). It is particularly interesting that TLR9 is linked to
expression of a growth factor receptor, signalling through
which affects growth and development in a tissue-specific man-
ner. Islet beta cells undergo significant growth and remodelling
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Fig. 7 Effect of TLR9 antagonist treatment on immune cells in Tlr9+/+
NOD mice. (a) Regulatory T cells (Foxp3+ Tregs) in pancreatic islets.
Immune cells were extracted from pancreatic islets isolated from the
female progeny (5–6 weeks old) of Tlr9+/+ NOD mice treated with
TLR9 antagonist ODN or control ODN during pregnancy (n = 3 pregnant
dams/group). Cells were stained with monoclonal antibodies to CD3,
CD4 and Foxp3. The percentage of Foxp3+CD4 T cells is shown after
gating for CD3+ cells (p = 0.235; n = 6 mice for both groups). (b)
Reduced naive (CD44−CD62L+) CD4+ Tcells in the spleen of the female
progeny (5–6-weeks of age) from TLR9 antagonist-treated pregnant
NOD mice. Splenocytes from these mice were isolated and stained with
monoclonal antibodies to CD3, CD4, CD44 and CD62L. The percentage
of naive CD4+ T cells is shown after gating for CD3+CD4+ T cells (p =
0.0011; n = 7 mice for both groups). (c) Increased memory
(CD44+CD62L−) CD4+ T cells in the spleen of the female progeny (5–
6 weeks old) from TLR9 antagonist-treated pregnant NOD mice.
Splenocytes from these mice were isolated and stained with monoclonal
antibodies to CD3, CD4, CD44 and CD62L. The percentage of memory
CD4+ T cells is shown after gating for CD3+CD4+ T cells (p = 0.0106;
n = 7 mice for both groups). Two independent experiments were carried
out. Data are expressed as means (SD). Data were analysed by two-tailed
unpaired Student’s t test. *p < 0.05, **p < 0.01
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Fig. 8 The TLR9 inhibitor chloroquine promotes islet beta cell develop-
ment. Pregnant Tlr9+/+NODmice were treated with chloroquine (20 μg/g
body weight, i.p. injection, twice, 3 or 4 days apart) or PBS (control). (a)
Chloroquine treatment increased CD140a+ beta cell per cent. Islet beta
cells from 4-week-old female progeny of chloroquine-treated (black cir-
cles) or PBS-treated (white circles) pregnant Tlr9+/+ NOD mice (n = 3
pregnant dams) were examined by flow cytometry for CD140a expres-
sion (p = 0.0017; n = 4 mice for both; pancreatic islets from two mice
were pooled as one sample). (b) Chloroquine treatment increased the
number of islets. Pancreatic islets were isolated and counted from 4-
week-old female progeny of chloroquine-treated (black circles) or PBS-
treated (white circles) mothers (p = 0.005; n = 6 for both). (c) Chloroquine
treatment increased the number of beta cells. Islet beta cells were isolated
and stained with monoclonal antibodies to CD45 and FluoZin-AM. The
number of beta cells (CD45−Fluozin-AM+) was counted by flow cytom-
etry (p = 0.0188; n = 5 mice for both). Two independent experiments were
performed, with n = 4–6 mice per group per experiment. Data are
expressed as means (horizontal line). Data were analysed by two-tailed
unpaired Student’s t test. *p < 0.05, **p < 0.01
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during prenatal development [41] but the capacity for
neogenesis and regeneration of beta cells is lost later in life.
Marked beta cell hyperplasia occurs during neonatal develop-
ment and the role of CD140a in beta cell proliferation is age-
dependent [29]. In our experiments, brief treatment of preg-
nant Tlr9+/+ NOD mice with a TLR9 antagonist oligonucleo-
tide, as well as with chloroquine (which also antagonises
TLR9), significantly enhanced beta cell growth. This was ac-
companied by enhanced insulin secretion in response to glu-
cose stimulation, as the mice developed into adulthood, and
also coincided with an increased percentage of CD140a-
expressing beta cells, suggesting the association of the two
processes. We did not examine the effect of chloroquine on
islet beta cells directly in vitro, as we think it is important to
study the drug effect in vivo; although chloroquine is not
specific for islet beta cells, we did not observe any noticeable
systemic adverse effects.
TLR signalling in mammals has been mainly linked to
innate immunity. Our results suggest a novel effect of TLR9
on growth and development in addition to its role in innate
immunity. The fact that this brief inhibition of TLR9 signal-
ling, early in life, led to protection from autoimmune diabetes
development in Tlr9+/+ NOD mice, similar to the phenotype
seen in Tlr9−/− NOD mice, suggests a possible means of im-
proving islet reserve. The inhibition of the development of
diabetes is likely to be a combination of increased beta cell
capacity (referring to increase in number of beta cells, im-
proved sensitivity to glucose and increased insulin produc-
tion), together with the immunological changes that we, and
others, have previously reported [9, 10]. These changes in-
clude increased expression of CD73 and reduced production
of proinflammatory cytokines [10], together with a reduction
in activation of autoreactive diabetogenic CD8 T cells, all of
which occur as a result of TLR9 inhibition [9]. Inhibition of
TLR9 has not been explored in human type 1 diabetes; how-
ever, pre-clinical tests for identifying an effective and safe
dose, route and timing of any potential agent would need to
be conducted first.
We conclude that TLR9 negatively regulates the develop-
ment of pancreatic islets and insulin-secreting beta cells, me-
diated, at least in part, by CD140a. Our findings provide novel
insight into the function of TLR9 beyond the immune cells
and also suggest a new direction for the design of preventive
and/or therapeutic strategies for diabetes.
Acknowledgements We thank X. Zhang (Internal Medicine, Yale
University, USA) for taking excellent care of the animals used in this
study.
Data availability Data are available on request from the authors.
Funding This work was funded by the National Institutes of Health
(grant numbers: DK-092882, DK-100500 and Mouse Genetic Core of
P30 DK-405735).
Duality of interest The authors declare that there is no duality of interest
associated with this manuscript.
Contribution statement ML, JP, NT, CH and JG performed experiments.
ML, JP, JAP, FSWand LWanalysed the data and LH and HZ carried out
bioinformatic analysis. LW and FSW wrote the manuscript and JAP
edited the manuscript. All authors reviewed and approved themanuscript.
LW initiated and designed the study and is the guarantor of the work.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
1. WenL, Peng J, Li Z,Wong FS (2004) The effect of innate immunity
on autoimmune diabetes and the expression of Toll-like receptors
on pancreatic islets. J Immunol 172:3173–3180
2. Giarratana N, Penna G, Amuchastegui S, Mariani R, Daniel KC,
Adorini L (2004) A vitamin D analog down-regulates proinflam-
matory chemokine production by pancreatic islets inhibiting T cell
recruitment and type 1 diabetes development. J Immunol 173:
2280–2287
3. Rasschaert J, Ladriere L, Urbain M et al (2005) Toll-like receptor 3
and STAT-1 contribute to double-stranded RNA+ interferon-
gamma-induced apoptosis in primary pancreatic beta-cells. J Biol
Chem 280:33984–33991
4. Dogusan Z, Garcia M, Flamez D et al (2008) Double-stranded
RNA induces pancreatic beta-cell apoptosis by activation of the
toll-like receptor 3 and interferon regulatory factor 3 pathways.
Diabetes 57:1236–1245
5. Song MJ, Kim KH, Yoon JM, Kim JB (2006) Activation of Toll-
like receptor 4 is associated with insulin resistance in adipocytes.
Biochem Biophys Res Commun 346:739–745
6. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS (2006)
TLR4 links innate immunity and fatty acid-induced insulin resis-
tance. J Clin Invest 116:3015–3025
7. Reyna SM, Ghosh S, Tantiwong P et al (2008) Elevated toll-like
receptor 4 expression and signaling in muscle from insulin-resistant
subjects. Diabetes 57:2595–2602
8. Wong FS, Hu C, Zhang L et al (2008) The role of Toll-like receptors
3 and 9 in the development of autoimmune diabetes in NOD mice.
Ann N YAcad Sci 1150:146–148
9. Zhang Y, Lee AS, Shameli A et al (2010) TLR9 blockade inhibits
activation of diabetogenic CD8+ T cells and delays autoimmune
diabetes. J Immunol 184:5645–5653
10. Tai N, Wong FS, Wen L (2013) TLR9 deficiency promotes CD73
expression in T cells and diabetes protection in nonobese diabetic
mice. J Immunol 191:2926–2937
11. Lamphier MS, Sirois CM, Verma A, Golenbock DT, Latz E (2006)
TLR9 and the recognition of self and non-self nucleic acids. Ann N
YAcad Sci 1082:31–43
12. Means TK, Latz E, Hayashi F, Murali MR, Golenbock DT, Luster
AD (2005) Human lupus autoantibody-DNA complexes activate
DCs through cooperation of CD32 and TLR9. J Clin Invest 115:
407–417
13. Martin DA, Elkon KB (2006) Intracellular mammalian DNA stim-
ulates myeloid dendritic cells to produce type I interferons predom-
inantly through a toll-like receptor 9-independent pathway. Arthritis
Rheum 54:951–962
Diabetologia
14. Wagner H, Bauer S (2006) All is not Toll: new pathways in DNA
recognition. J Exp Med 203:265–268
15. Barak B, Feldman N, Okun E (2014) Toll-like receptors as devel-
opmental tools that regulate neurogenesis during development: an
update. Front Neurosci 8:272
16. Bonner-Weir S (2001) Beta-cell turnover: its assessment and impli-
cations. Diabetes 50(Suppl 1):S20–S24
17. Hardikar AA (2004) Generating new pancreas from old. Trends
Endocrinol Metab 15:198–203
18. Yang KM, Li AD, Mei Y, Zhou HY, Li H, Yang HJ (2006) Islet
formation and regeneration. Chin Med Sci J 21:27–32
19. Khadra A, Schnell S (2015) Development, growth and maintenance
of beta-cell mass: models are also part of the story. Mol Asp Med
42:78–90
20. Hemmi H, Takeuchi O, Kawai T et al (2000) A Toll-like receptor
recognizes bacterial DNA. Nature 408:740–745
21. Szot GL, Koudria P, Bluestone JA (2007) Murine pancreatic islet
isolation. J Vis Exp: JoVE 255
22. Jayaraman S (2011) Assessment of beta cell viability. Current pro-
tocols in cytometry. Chapter 6: Unit 6 27. https://doi.org/10.1002/
0471142956.cy0627s55
23. Millet I, Wong FS, Gurr W et al (2006) Targeted expression of the
anti-apoptotic gene CrmA to NOD pancreatic islets protects from
autoimmune diabetes. J Autoimmun 26:7–15
24. Chervonsky AV (2010) Influence of microbial environment on au-
toimmunity. Nat Immunol 11:28–35
25. Li YY, Pearson JA, Chao C et al (2017) Nucleotide-binding oligo-
merization domain-containing protein 2 (Nod2) modulates T1DM
susceptibility by gut microbiota. J Autoimmun 82:85–95
26. Ferber S, Halkin A, Cohen H et al (2000) Pancreatic and duodenal
homeobox gene 1 induces expression of insulin genes in liver and
ameliorates streptozotocin-induced hyperglycemia. Nat Med 6:
568–572
27. Soyer J, Flasse L, Raffelsberger W et al (2009) Rfx6 is an Ngn3-
dependent winged helix transcription factor required for pancreatic
islet cell development. Development 137:203–212
28. Wilson ME, Scheel D, German MS (2003) Gene expression cas-
cades in pancreatic development. Mech Dev 120:65–80
29. Chen H, Gu X, Liu Y et al (2011) PDGF signalling controls age-
dependent proliferation in pancreatic beta-cells. Nature 478:349–
355
30. Akirav EM, Lebastchi J, Galvan EM et al (2011) Detection of beta
cell death in diabetes using differentially methylated circulating
DNA. Proc Natl Acad Sci U S A 108:19018–19023
31. Gee KR, Zhou ZL, Qian WJ, Kennedy R (2002) Detection and
imaging of zinc secretion from pancreatic beta-cells using a new
fluorescent zinc indicator. J Am Chem Soc 124:776–778
32. Assmann A, Hinault C, Kulkarni RN (2009) Growth factor control
of pancreatic islet regeneration and function. Pediatr Diabetes 10:
14–32
33. Kushner JA, Ciemerych MA, Sicinska E et al (2005) Cyclins D2
and D1 are essential for postnatal pancreatic beta-cell growth. Mol
Cell Biol 25:3752–3762
34. TetaM, Long SY,WartschowLM, RankinMM,Kushner JA (2005)
Very slow turnover of beta-cells in aged adult mice. Diabetes 54:
2557–2567
35. Tallquist M, Kazlauskas A (2004) PDGF signaling in cells and
mice. Cytokine Growth Factor Rev 15:205–213
36. GeneCards Human Gene Database. PDGRFA gene. Available from
www.genecards.org/cgi-bin/carddisp.pl?gene=PDGFRA.
Accessed 13 Jul 2018
37. Ghosh S, May MJ, Kopp EB (1998) NF-kappa B and Rel proteins:
evolutionarily conserved mediators of immune responses. Annu
Rev Immunol 16:225–260
38. Gilmore TD, Gerondakis S (2011) The c-Rel transcription factor in
development and disease. Genes Cancer 2:695–711
39. Ramakrishnan P, Yui MA, Tomalka JA, Majumdar D,
Parameswaran R, Baltimore D (2016) Deficiency of nuclear
factor-κB c-Rel accelerates the development of autoimmune dia-
betes in NOD mice. Diabetes 65:2367–2379
40. KonoH, RockKL (2008) How dying cells alert the immune system
to danger. Nat Rev Immunol 8:279–289
41. Trudeau JD, Dutz JP, Arany E, Hill DJ, Fieldus WE, Finegood DT
(2000) Neonatal beta-cell apoptosis: a trigger for autoimmune dia-
betes? Diabetes 49:1–7
Diabetologia
